DCTH

#3154
Delcath Systems Inc
10.8800 USD
+4.11%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
10.8800
10.8800
Rango anual
8.1200
11.1500
Cambio diario
+4.11%
Variación mensual
+13.45%
Variación en los últimos 6 meses
+5.22%
Cambio anual
+5.22%
Cierres anteriores
10.4500
Abrir
10.8800
Bid
Ask
Mínimo
10.8800
High
10.8800
Volumen
45
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 378.0385 M
  • Employee 156
  • Founded 1988
  • CEO Gerard Michel
  • Website www.delcath.com
  • Headquarter Delaware, United States
  • FIGI BBG000BY2VF5
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
144.29
Relación precio/flujo de caja
4.73

Delcath Systems Inc

Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.

Noticias